eISSN: 2081-2833
ISSN: 2081-0016
Medycyna Paliatywna/Palliative Medicine
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
Share:
Share:
abstract:
Guidelines/recommendations

Hyponatraemia in patients with malignancies – causes, treatment, and prognosis

Kaja Balcerowska
1
,
Adrianna Zabłotnia
1
,
Edyta Julia Twardowska
1
,
Paulina Piechowicz
1
,
Tomasz Dzierżanowski
1, 2

  1. Klinika Medycyny Paliatywnej, Warszawski Uniwersytet Medyczny, Warszawa, Polska
  2. Caritas Diecezji Warszawsko-Praskiej, Warszawa, Polska
Medycyna Paliatywna 2024; 16(4)
Online publish date: 2024/10/14
View full text Get citation
 
PlumX metrics:
Hyponatraemia, defined as serum sodium concentration below 135 mmol/l, is significantly common in patients with malignancies. It usually causes mild neurological and cardiovascular symptoms but can also be a life-threatening condition. Hyponatraemia is a risk factor for bad prognosis. It affects lower survival time and worse response to anticancer treatment. It may be due to the tumour, anticancer treatment, or comorbidities. The most common cause of hyponatraemia in patients with malignancies is a syndrome of inappropriate antidiuretic hormone secretion. After diagnosing hyponatraemia, the duration and severity of symptoms should be determined. Acute and life-threatening hyponatraemia requires immediate treatment with 3% saline. Chronic hyponatraemia treatment targets the cause.
keywords:

hyponatraemia, prognosis, SIADH, chemotherapy, osmolality, treatment

FEATURED PRODUCTS
BOOKS
Medycyna Paliatywna
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.